IBJNews

Analyst: Lilly solid even without pipeline

Back to TopCommentsE-mailPrintBookmark and Share

While Eli Lilly and Co.’s stock price is up 16 percent in the past four months, a new analyst covering the company thinks it has more room to grow. And that’s even without launching a new Alzheimer’s drug anytime soon.

Citi Research analyst Andrew Baum thinks Lilly shares are undervalued because investors don’t appreciate the older assets Lilly already has, particularly its lung cancer drug Alimta, its animal health business Elanco, its diabetes products and sales of all products in emerging markets.

Baum assumes those parts of Lilly’s business will add an extra $8.5 billion in revenue by 2018, substantially offsetting the more than $10 billion in annual revenue Lilly is shedding as patents on five blockbuster drugs expire between 2010 and 2014.

“The market appears to be materially underestimating the long-term earnings power and value in the base business given the longevity of Alimta cash flows post-2016, and increasing diabetes, Elanco and [emerging markets] exposure,” Baum wrote in his Nov. 29 report. He expects Lilly shares to rise another 16 percent, to $55 apiece.

While many investors warmed to Lilly in late summer and early fall because its experimental Alzheimer’s drug solanezumab showed some promise, Baum thinks they missed a recent favorable patent ruling from a federal court that will effectively extend Alimta's sales life for Lilly an additional five years.

If that's true, Lilly would enjoy Alimta’s $2.5 billion until 2021, as opposed to 2016, as investors had assumed.

“Following substantial and detailed patent analysis outlined in this report, we see a very low probability of generic Alimta launches in U.S. and Japan until the expiry of the ’209 method of use patent and equivalents post-2021,” Baum wrote. He does, however, expect some generic competition in European markets.

At Greenfield-based Elanco, Baum expects sales to keep growing at double digits, and double from $2 billion this year to $4 billion in 2018.

“We anticipate animal health assets will continue to re-rate given upward pressure on margins from food supply demand imbalance, new product innovations and high barriers to entry,” Baum wrote.

In diabetes, Baum expects Lilly’s annual sales to rise from $4 billion this year to $6.5 billion in 2018. That will be driven by Tradjenta, launched in conjunction with Boehringer Ingelheim GmbH, which Baum expects to become the third-best-selling drug in its class, reaching $2 billion in annual sales.

Baum also expects success for Lilly’s experimental drug dulaglutide—which is supposed to be a better version of the drugs Byetta and Bydureon, which Lilly sold back to its partners Amylin Pharmaceuticals Inc.

And in emerging markets, Baum expects Lilly to more than double sales from $3 billion this year to $6.6 billion in 2018. He expects emerging markets to generate $9 billion in sales for Lilly by 2021.

As for the Alzheimer’s drug solanezumab, Baum thinks it will be approved—but not until 2017, after Lilly runs another large Phase 3 clinical trial on the drug.

He acknowledges the political pressures to approve an Alzheimer’s drug now—and solanezumab is the first to show some effect on the disease progression, albeit a small effect. But Baum thinks an early approval of solanezumab stands a less than 5 percent chance of success.

“While Lilly may not have taken potential near-term approval for solanezumab ‘off the table,’ we are highly doubtful that solanezumab can be approved using any of the 'tools' cited by Lilly, in the absence of additional clinical data,” Baum wrote.

By 2017, he expects Switzerland-based Roche Group to also have an Alzheimer’s drug approved, meaning Lilly will have to share the market. He pegs solanezumab’s peak annual sales at $2 billion.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Good Day I am Mr (Victoria Wright) from United state of America, i stayed in NEW YORK, and i have a broke up business, until i found this company email who help me to gain a loan for business,, and now i want to used this short medium to congratulate the below company for the fast and safe money they loan to me without any form of collateral, i loan 500,000USD from the company to save my business and lots more, i saw their mail on the internet, everyone always give testimony for what they did, so i quickly contacted them and they all did everything for me without stress and my money was sent to my account just 3 days later, i was surprise and i feel so glad, now i have a standard business control agent who help me, now i will advice those who need urgent loan to contact him at the bellow email:zenithfirm12@gmail.com

  2. NOTICE:This is to inform the general public that Vampires are real. My name is James Franklyn.,am an agent of vampire,am here to introduce our new world trend to you,a world of vampire where life get easier,we have made so many persons vampires and have turned them rich,you will be assured long life and prosperity,you shall be made to be very sensitive to mental alertness,stronger and also very fast,you will not be restricted to walking at night only even at the very middle of broad day light you will be made to walk.In case you are wildly oppressed by some unscrupulous persons we can still help you fight them.Your protection is assured immediately you join.Just contact the bellow email if you are interested we are here to attend to you anytime you want us. Contact the bellow email for more details. Email:vampirescreed@hotmail.com Sincerely: James Franklyn.

  3. Bravo! Someone else that is willing to speak the truth! Bravo!_____NBCSN is available in almost 2 MILLION more homes than just a few years ago, but Indycar STILL gets less total viewers than it did just a few years ago when NBC took over Versus. Attendance and ratings cratered with the end of season races (just when the title battle got "interesting" HAH!__________And now...new race in Basilia, where Miles celebrated the "rich history" of Indycar racing there. Rich history? What, 7 events in the 100 years of AOW? Yep, some history. Well, at least its an oval. It's not??? Are you kidding me??? Gosh darn road racin furriners.

  4. PURITY RAY LOAN OFFER........ Have you been denied by your banks,or are you in need of of an urgent loan to pay of your bills we are capable of giving loans @ cheaper rate to interested individuals, student, companies and members of the public in need of finance to settle bills, we do offer considerable loans which you can count on. For more information on our various types of loan,then you will have to contact PURITY RAY LOAN FIRM, to help you achieve your desire LOAN APPLICATION FORM TO BE FILLED BORROWERS INFORMATION * Full name:………………………. * SEX * ……………………………. * Country………………………….. * State:……………………………. * Land:…………………………….. * Occupation:…………………….. * phone number:…………………. * Telephone: ………………………….. * Age:………………………………. * Amount needed as loan:……… * Loan Duration:………………….. * Propose of Loan:……………….. * Annual revenue:………………… * Monthly Income:……………….. * Guarantee:………………………. * Payment: monthly or annually Email.....purityrayloanfirm@gmail.com Thank you and God bless Mr Purity Ray PURITY RAY LOAN FIRM we tend to serve you better

  5. Problem: most of the people responding to this article don't know about this service AT ALL! Why? Lack of awareness. This isn't IndyGo. This is CIRTA: might as well be the mattress company because they are asleep at the wheel - something like 3 directors over the last year? Playing with federal grant money is great! This "region" wants commuter rail service, has spent MILLIONS on Transportation studies yet can't even support a commuter bus line? This is largely for suburban riders to get to downtown - not for "service people to work in our hotels and restaurants" ! Get your head out of your backside!! These are professionals, students etc. that don't want to fight traffic, save some money on parking, gas, stress.... if CIRTA would put their federal money into widely promoting the sevive to Greenwood, Fishers & Carmel instead of finding directors and studies - this would be a successful service. Our family uses(d) it daily for the last several years - but the recent uncertainty & now unreliability due to cuts from Carmel has been a problem. Now, costs us an additional $350/month for gas & parking ( $4200/year) plus vehicle wear, service, environmental impact ... YES - this REGION needs this this type of service in order to keep growing and getting the people it needs to fill skilled positions in downtown Indianapolis. Think outside of your own car !!!

ADVERTISEMENT